MMN (Multifocal Motor Neuropathy)
Multifocal motor neuropathy is a rare condition affecting the peripheral nerves that control muscle movement. Unlike CIDP, MMN causes progressive, asymmetric weakness without significant sensory loss. IVIG is the only proven treatment — corticosteroids and plasma exchange are ineffective and may worsen the disease.
You may qualify for clinical trials that provide Gamunex-C at no cost
Clinical trials may give you access to this treatment while helping advance medical research
Search TrialsIVIG is the first-line and only proven treatment for MMN. Corticosteroids are contraindicated and may worsen the condition. Insurers sometimes inappropriately request a corticosteroid trial — this should be challenged with clinical evidence. Dose optimization and infusion frequency are closely scrutinized.
Diagnosis confused with ALS or CIDP by non-specialist reviewer
Very Common
IVIG dose or frequency exceeds payer limits
Common
Required nerve conduction studies not submitted
Common
Anti-GM1 antibody testing not documented
Occasional
Payer requests trial of corticosteroids (which are contraindicated in MMN)
Occasional
- 1.Emphasize that corticosteroids are contraindicated in MMN — this distinguishes it from CIDP
- 2.Include nerve conduction study results showing conduction block
- 3.Document anti-GM1 antibody status (positive in ~50% of cases, but negative does not rule out MMN)
- 4.Show functional improvement or stabilization with IVIG treatment
- 5.Request peer-to-peer with a neuromuscular specialist
Active clinical trials that may provide treatment at no cost.
Copay cards, patient assistance programs, and foundation grants for this condition's treatments.
Want to know what you'll actually pay?
Estimate your annual out-of-pocket cost with and without assistance programs.
Estimate My CostsDenied for MMN (Multifocal Motor Neuropathy) Treatment?
Ellen can decode your denial, find your appeal strategy, and generate your appeal letter — free.